Effectiveness of bendamustine in relapsed or refractory lymphoma cases: a Turkish Oncology Group study

Nuri Karadurmus¹, Semra Paydas², Ece Esin³, Zeki Gokhan Surmeli⁴, Birol Yildiz⁵, Ismail Erturk⁶, Erdinc Nayir⁷, Mutlu Dogan⁸, Ahmet Taner Sumbul⁹, Ibrahim Barista⁷, Emel Gurkan⁴, Ramazan Ocal⁷, Burhan Ferhanoglu¹⁰, Gokhan Ozgur¹¹, Yusuf Karakas¹², Sahin Lacin⁷, Sukru Ozaydin⁶, Halil Ibrahim Petekkaya¹², Necdet Uskent¹³

¹Department of Medical Oncology, Health Sciences University, Gulhane Training and Research Hospital, Ankara, Turkey
²Department of Medical Oncology, Faculty of Medicine, Cukurova University, Adana, Turkey
³Department of Medical Oncology, Health Sciences University, Dr. Abdurrahman Yurtaslan Training and Research Hospital, Ankara, Turkey
⁴Department of Medical Oncology, Medicalpark Hospital, Ankara, Turkey
⁵Department of Medical Oncology, Health Sciences University, Numune Training and Research Hospital, Ankara, Turkey
⁶Department of Medical Oncology, Faculty of Medicine, Baskent University, Adana, Turkey
⁷Department of Medical Oncology, Faculty of Medicine, Hacettepe University, Ankara, Turkey
⁸Department of Haematology, Faculty of Medicine, Cukurova University, Adana, Turkey
⁹Department of Haematology, Faculty of Medicine, Gazi University, Ankara, Turkey
¹⁰Department of Haematology, Faculty of Medicine, Koc University, Istanbul, Turkey
¹¹Department of Haematology, Health Sciences University, Gulhane Training and Research Hospital, Ankara, Turkey
¹²Department of Medical Oncology, Special Tinaztepe Hospital, Izmir, Turkey
¹³Department of Medical Oncology, Anatolian Health Center, Istanbul, Turkey

Submitted: 21 February 2018; Accepted: 7 August 2018
Online publication: 18 February 2019

Arch Med Sci 2021; 17 (4): 920–927
DOI: https://doi.org/10.5114/aoms.2019.83000
Copyright © 2019 Termedia & Banach

Abstract

Introduction: We aimed to investigate the efficacy and side effects of bendamustine in relapsed/refractory lymphoma patients in Turkey.
Material and methods: In this retrospective study, we included relapsed/refractory Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) patients who underwent multiple lines of chemotherapy. The primary endpoint was to determine the objective response and toxicity.
Results: Ninety-nine patients with a median age of 59.8 years were included in the study. Eighty-one patients had NHL (follicular lymphoma: 10, diffuse large B-cell lymphoma: 27, mantle-cell lymphoma: 18, marginal zone lymphoma: 9, small lymphocytic lymphoma/chronic lymphocytic leukemia: 17) and 18 patients had HL. The patients had previously received a median of three lines of chemotherapy (range: 2–8) except autologous stem cell transplantation (ASCT); 19 patients (HL: 11, NHL: 8) had undergone ASCT. The objective response rate (ORR) was 74.3%, the complete response rate was 57% (= 53), and the partial response rate was 16.6% (= 19). The overall survival (OS) rate at 1 year was 74.6%. The progression-free survival (PFS) rate at 1 year was 62.5%. The most common side effects were lymphopenia, anemia and neutropenia. Side effects which were observed as grade 3 and higher levels were lymphopenia (14.1%), neutropenia (10.1%) and fatigue (7.1%).
Conclusions: Objective response rate of bendamustine was found to be 74.3% in relapsed/refractory HL and NHL patients. It appears to be an effective option as a salvage treatment for patients who have previously received multiple lines of therapy.

Key words: bendamustine, lymphoma, Hodgkin lymphoma.
### Table I. Patient characteristics

| Parameter                              | DLBCL     | FL        | MCL       | MZL       | CLL/SLL   | HL        |
|----------------------------------------|-----------|-----------|-----------|-----------|-----------|-----------|
| Total, n (%)                           | 27 (100)  | 10 (100)  | 18 (100)  | 9 (100)   | 17 (100)  | 18 (100)  |
| Age [years]:                           | Median    | 71.4      | 66.9      | 65.6      | 62.7      | 64        | 28.2      |
|                                         | Range     | (27–89)   | (49–82)   | (49–79)   | (45–78)   | (37–85)   | (16–72)   |
| Gender, n (%):                         |           |           |           |           |           |           |
| Male                                   | 15 (55.6) | 6 (60)    | 15 (83.3) | 3 (33.3)  | 13 (76.5) | 13 (72.2) |
| Female                                 | 12 (44.4) | 4 (40)    | 3 (16.7)  | 6 (66.7)  | 4 (23.5)  | 5 (27.8)  |
| Stage at diagnosis:                    |           |           |           |           |           |           |
| I or II                                | 8 (29.6)  | 0 (0)     | 2 (11.1)  | 3 (33.3)  | 8 (47.1)  | 5 (27.8)  |
| III or IV                              | 19 (70.3) | 10 (100)  | 16 (88.9) | 6 (66.7)  | 9 (52.9)  | 13 (72.2) |
| Bulky disease at diagnosis:            |           |           |           |           |           |           |
| Present                                | 9 (33.3)  | 1 (10)    | 4 (22.2)  | 2 (22.2)  | 5 (29.4)  | 5 (27.8)  |
| Extranodal disease:                    |           |           |           |           |           |           |
| Present                                | 9 (33.3)  | 6 (60)    | 10 (55.6) | 7 (77.8)  | 4 (23.5)  | 6 (33.3)  |
| ECOG status, n (%):                    |           |           |           |           |           |           |
| 0 or 1                                 | 14 (51.9) | 7 (70)    | 11 (61.1) | 7 (77.8)  | 13 (76.5) | 16 (88.9) |
| 2 or 3                                 | 13 (48.1) | 3 (30)    | 7 (38.9)  | 2 (22.2)  | 4 (23.5)  | 2 (11.1)  |
| B symptoms, n (%):                     |           |           |           |           |           |           |
| Present                                | 7 (25.9)  | 3 (30)    | 4 (22.2)  | 4 (44.4)  | 7 (41.2)  | 13 (68.5) |
| Refractory to previous chemotherapy:   |           |           |           |           |           |           |
| Yes                                    | 15 (55.6) | 2 (22.2)  | 9 (50)    | 2 (22.2)  | 3 (18.8)  | 12 (66.7) |
| Disease duration* [months]:            | Median    | 14.5      | 39.2      | 32.8      | 22.2      | 34.2      | 36.6      |
|                                         | Range     | (2–140)   | (16–148)  | (4–67)    | (8–158)   | (15–114)  | (18–114)  |
| Previous treatments, n (%):            |           |           |           |           |           |           |
| Rituximab                              | 27 (100)  | 9 (90)    | 14 (77.8) | 8 (88.9)  | 14 (82.4) | 0 (0)     |
| ABVD                                   | 0 (0)     | 0 (0)     | 0 (0)     | 0 (0)     | 0 (0)     | 17 (94.4) |
| CHOP                                   | 25 (92.6) | 7 (70)    | 12 (66.7) | 3 (33.3)  | 6 (35.3)  | 0 (0)     |
| FC                                     | 1 (3.7)   | 2 (20)    | 0 (0)     | 0 (0)     | 11 (64.7) | 0 (0)     |
| CVP                                    | 4 (14.8)  | 3 (30)    | 3 (16.7)  | 3 (33.3)  | 6 (35.3)  | 1 (5.6)   |
| DHAP                                   | 0 (0)     | 0 (0)     | 3 (16.7)  | 0 (0)     | 0 (0)     | 10 (55.6) |
| ICE                                    | 8 (29.6)  | 1 (10)    | 3 (16.7)  | 0 (0)     | 1 (5.9)   | 9 (50)    |
| Other                                  | 13 (48.1) | 1 (10)    | 8 (44.4)  | 0 (0)     | 2 (11.8)  | 12 (66.7) |
| Radiotherapy                           | 11 (40.7) | 4 (40)    | 3 (16.7)  | 1 (11.1)  | 0 (0)     | 6 (33.3)  |
| Autologous SCT                         | 1 (3.7)   | 2 (20)    | 5 (27.8)  | 0 (0)     | 0 (0)     | 11 (61.1) |
| Treatment setting, n (%):              |           |           |           |           |           |           |
| 2nd-line                               | 10 (37)   | 4 (40)    | 9 (53)    | 8 (80)    | 8 (47.1)  | 1 (5.6)   |
| 3rd-line                               | 12 (44.4) | 2 (20)    | 5 (29.4)  | 1 (10)    | 7 (41.2)  | 1 (5.6)   |
| Beyond 3rd-line                        | 5 (18.5)  | 4 (40)    | 3 (17.6)  | 1 (10)    | 2 (11.8)  | 16 (88.8) |
| Median                                 | 3         | 3         | 2         | 2         | 3         | 5         |
| Range                                  | (2–6)     | (2–5)     | (2–5)     | (2–7)     | (2–5)     | (2–8)     |

The percentages in parentheses are column percentages. *Disease duration refers to the time from initial diagnosis of lymphoma to the initiation of study treatment. ABVD – Adriamycin, bleomycin, vinblastine, dacarbazine, CHOP – cyclophosphamide, doxorubicin, vincristine, prednisone, CLL/SLL – chronic lymphocytic lymphoma/small lymphocytic lymphoma, CVP – cyclophosphamide, vincristine, prednisone, DHAP – dexamethasone, cytarabine, cisplatin, DLBCL – diffuse large B-cell lymphoma, ECOG – Eastern Cooperative Oncology Group, FC – fludarabine, cyclophosphamide, FL – follicular lymphoma, HL – Hodgkin lymphoma, ICE – ifosfamide, carboplatin, etoposide, MCL – mantle-cell lymphoma, MZL – marginal zone lymphoma, SCT – stem cell transplantation.
Effectiveness of bendamustine in relapsed or refractory lymphoma cases: a Turkish Oncology Group study

Patients; and as fifth-line treatment in patients with HL. Patient demographics and disease characteristics are summarized in Table I.

Treatment exposure and efficacy

Patients received a median of 4 cycles of bendamustine in the DLBCL group and 6 cycles in other groups (Table II). A total of 538 cycles of bendamustine were administered. The median duration of bendamustine treatment ranged from 4.5 (in the DLBCL group) to 5.6 months (in the MCL group). The most commonly preferred schedule was 90 mg/m² administered every three weeks. Objective response rates were 55.6% in DLBCL, 61.1% in HL, 72.2% in MCL, 80% in FL, 88.2% in CLL/SLL, and 88.9% in MZL patients (Table III). The majority of

Table II. Treatment exposure

| Parameter | DLBCL (n = 27) | FL (n = 10) | MCL (n = 18) | MZL (n = 9) | CLL/SLL (n = 17) | HL (n = 18) |
|-----------|----------------|------------|-------------|-------------|-----------------|------------|
| Treatment duration [months]: | | | | | | |
| Median | 4.5 | 5.3 | 5.6 | 4.9 | 5.3 | 5.3 |
| Range | (0.7–37.3) | (1.7–7.6) | (1.7–28.7) | (1.6–6.4) | (3.6–9) | (0.3–22) |
| No. of cycles: | | | | | | |
| Median | 4 | 6 | 6 | 6 | 6 | 6 |
| Range | (1–8) | (2–9) | (2–38) | (2–8) | (4–6) | (1–10) |
| Bendamustine dosage, n (%): | | | | | | |
| 90 mg/m² | 17 (63) | 8 (80) | 16 (88.9) | 9 (100) | 17 (100) | 14 (77.8) |
| 100 mg/m² | 9 (33.3) | 2 (20) | 2 (11.1) | 0 (0) | 0 (0) | 1 (5.6) |
| 120 mg/m² | 1 (3.7) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 3 (16.7) |

Note: The percentages in parentheses are column percentages. DLBCL – diffuse large B-cell lymphoma, FL – follicular lymphoma, HL – Hodgkin lymphoma, MCL – mantle cell lymphoma, MZL – marginal zone lymphoma.

Table III. Efficacy results

| Parameter | DLBCL (n = 27) | FL (n = 10) | MCL (n = 18) | MZL (n = 9) | CLL/SLL (n = 17) | HL (n = 18) |
|-----------|----------------|------------|-------------|-------------|-----------------|------------|
| Best response, n (%): | | | | | | |
| Complete response | 12 (44.4) | 6 (60) | 11 (61.1) | 8 (88.9) | 9 (52.9) | 7 (38.8) |
| Partial response | 3 (11.1) | 2 (20) | 2 (11.1) | 0 (0) | 6 (35.3) | 4 (22.2) |
| Stable disease | 3 (11.1) | 0 (0) | 2 (11.1) | 0 (0) | 1 (5.9) | 5 (27.8) |
| Progressive disease | 8 (29.6) | 2 (20) | 2 (11.1) | 1 (11.1) | 0 (0) | 1 (5.6) |
| Unknown | 1 (3.7) | 0 (0) | 0 (0) | 1 (5.6) | 0 (0) | 1 (5.6) |
| ORR, % (95% CI) | 55.6 (35.3–74.5) | 80 (44.4–97.5) | 72.2 (46.5–90.3) | 88.9 (51.8–99.7) | 88.2 (63.6–98.5) | 61.1 (38.6–79.7) |
| Progression-free survival: | | | | | | |
| No. of events | 13 | 7 | 8 | 2 | 5 | 9 |
| 1-year PFS, % (95% CI) | 43 (21.1–63.3) | 50 (18.4–75.3) | 63.9 (36.5–82) | 71.4 (25.8–92) | 85.7 (53.9–96.2) | 61.1 (35.3–79.2) |
| 2-year PFS, % (95% CI) | 43 (21.1–63.3) | 40 (12.3–67) | 53.3 (24.3–75.6) | 71.4 (25.8–92) | 55.1 (22–79) | 45.8 (20.9–67.8) |
| Median PFS [months] (95% CI) | 11.1 (5.5–16.7) | 8.6 (0–17.9) | 25.9 (3.1–48.6) | NE | NE | 13.2 (NE) |
| Overall survival: | | | | | | |
| No. of events | 12 | 3 | 5 | 2 | 3 | 6 |
| 1-year OS, % (95% CI) | 48.2 (25.3–67.9) | 88.9 (43.3–98.4) | 74.9 (45.6–89.9) | 71.4 (25.8–92) | 92.9 (59.1–99) | 71.8 (47.2–87.9) |
| 2-year OS, % (95% CI) | 41.3 (25.3–67.9) | 76.2 (33.2–93.5) | 74.9 (45.6–89.9) | 71.4 (25.8–92) | 73.9 (37.9–91) | 64.6 (37–82.5) |

Note: The percentages in parentheses are column percentages. CI – confidence interval, CLL/SLL – chronic lymphocytic lymphoma/small lymphocytic lymphoma, DLBCL – diffuse large B-cell lymphoma, FL – follicular lymphoma, HL – Hodgkin lymphoma, MCL – mantle cell lymphoma, MZL – marginal zone lymphoma, NE – not estimable, ORR – objective response rate, OS – overall survival, PFS – progression-free survival.
the responses were complete responses ranging from 38.8% in HL to 88.9% in MZL patients (Table III). At a median follow-up of 22 months, the estimates of 1-year PFS were 43% in DLBCL, 50% in FL, 61.1% in HL, 64.6% in MCL, 71.4% in MZL, and 85.7% in CLL/SLL groups; and the estimates of 1-year OS were 48.2% in DLBCL, 71.4% in MZL, 71.8% in HL, 74.9% in MCL, 88.9% in FL, and 92.9% in CLL/SLL (Table III, Figure 1).

After bendamustine treatment, stem cell transplantation (SCT) was performed in 8% of patients who had at least a partial response. Autologous SCT was performed in 6 patients and two of them had CR (one DLBCL and one HL). Allogeneic SCT was performed in two HL patients who achieved CR with bendamustine. Details of bendamustine efficacy in bridging to SCT and rates of SCT are shown in Table IV.

Safety and adverse events

Hematological adverse events associated with bendamustine were common but usually low grade; the incidence of lymphopenia, anemia, neutropenia and thrombocytopenia was 74.7%, 64.6%, 61.6%, and 45.5%, respectively (Table V). Nausea and diarrhea were observed in 41.4% and 27.3% of the patients. Other toxicities were elevated alanine aminotransferase (25.2%), peripheral edema (22.2%), elevated aspartate aminotransferase (21.2%), rash (17.2), and alopecia (15.1%). At least one dose delay or dose reduction was required in 25.3% and 11.1% of patients, respectively. Adverse events did not necessitate treatment discontinuation in any patients. No deaths were attributed to bendamustine treatment. At a median follow-up duration of 22 months no secondary malignancies have been recorded.

Discussion

Bendamustine is a bimodal chemotherapeutic agent having both alkylating and antimetabolite properties. The combined cytotoxic activity of bendamustine has resulted in high response rates and durable responses in patients with heavily pretreated indolent and aggressive lymphomas. This study presents the longitudinal multicenter results of bendamustine in heavily pretreated indolent B-NHL, DLBCL and HL patients. In our study,
Effectiveness of bendamustine in relapsed or refractory lymphoma cases: a Turkish Oncology Group study

Table IV. Post-bendamustine stem cell transplantation rates

| SCT     | Lymphoma type | N   | %         | Bendamustine dose [mg/m²] and number of cycles | Post-bendamustine response |
|---------|---------------|-----|-----------|-----------------------------------------------|----------------------------|
| Autologous    |               |     |           |                                               |                            |
| Total        |               | 6   |           |                                               |                            |
| HL          |               | 3   |           | 90–90–120/4–9–4                               | 1 CR and 2 PR              |
| FL          |               | 1   |           | 90/2                                          | PR                         |
| DLBCL       |               | 1   |           | 100/8                                         | CR                         |
| MCL         |               | 1   |           | 90/4                                          | PR                         |
| Allogeneic   |               | 2   |           |                                               |                            |
| HL          |               | 2   |           | 100–90/4                                      | CR                         |

DLBCL – CR – complete response, diffuse large B-cell lymphoma, FL – follicular lymphoma, HL – Hodgkin lymphoma, MCL – mantle-cell lymphoma, PR – partial response, SCT – stem cell transplantation.

Table V. Adverse events

| Adverse event* | Any grade | Grade 3 or 4 (%) |
|----------------|-----------|-----------------|
|                | All (%) (n = 99) | Among responders (%) (n = 70) | Among non-responders (%) (n = 29) | (n = 99) |
| Lymphopenia    | 74 (74.7)     | 53 (75.7)       | 21 (72.4)       | 14 (14.1) |
| Anemia         | 64 (64.6)     | 43 (61.4)       | 21 (72.4)       | 5 (5.1)   |
| Neutropenia    | 61 (61.6)     | 47 (67.1)       | 14 (48.3)       | 10 (10.1) |
| Fatigue        | 50 (50.5)     | 39 (55.7)       | 11 (37.9)       | 7 (7.1)   |
| Thrombocytopenia | 45 (45.5)   | 31 (44.3)       | 14 (48.3)       | 5 (5.1)   |
| Nausea         | 41 (41.4)     | 29 (41.4)       | 12 (41.4)       | 2 (2)     |
| Diarrhea       | 27 (27.3)     | 19 (27.1)       | 8 (27.6)        | 1 (1)     |
| Elevated ALT   | 25 (25.2)     | 16 (22.9)       | 9 (31)          | 1 (1)     |
| Peripheral edema | 22 (22.2) | 16 (22.9)       | 6 (20.7)        | 0 (0)     |
| Elevated AST   | 21 (21.2)     | 14 (20)         | 7 (24.1)        | 0 (0)     |
| Rash           | 17 (17.2)     | 12 (17.1)       | 5 (17.2)        | 0 (0)     |
| Alopecia       | 15 (15.1)     | 13 (18.6)       | 2 (6.9)         | NA        |

*Adverse events observed in 15% or more of the patients, and grade 3 or 4 adverse events observed in 2% or more of the patients are listed. ALT – alanine aminotransferase, AST – aspartate aminotransferase.

there were 99 patients with diverse histologies and defined by their primary oncologist/hematologist as refractory patients. Hence, the results are important in terms of a possible treatment option in a patient group with dismal prognosis.

The number of cycles of administered bendamustine, treatment duration, dose intensity and the median number of previous chemotherapy regimens are the important parameters in terms of bendamustine efficacy. Median administered number of cycles [8–11] and median duration of treatment (4.5–5.6 months) were comparable with the accepted dose intensity [9–11]. The bendamustine dose was 90 to 120 mg/m² per cycle and more than 80% of indolent lymphoma patients received 90 mg/m² as compared to 37% of DLBCL patients who received at least 100 mg/m². None of our patients was scheduled for lower doses of bendamustine (such as 60 mg/m²). The median number of prior regimens administered was two for indolent B-NHL, three for DLBCL, and five for HL. These results were found to be similar to the results of Ghesquieres et al. and Ohmachi et al. [11, 12]. However, our HL patient population was more heavily pre-treated than the others. None of the patients required discontinuation of treatment due to adverse events.

In this trial, ORR was found as 55.6% in patients with heavily pretreated DLBCL with the combination of bendamustine and rituximab. The estimated 1-year PFS and OS were found to be 43% and 48.2%. These results are comparable with the results of more aggressive R-ESHAP and R-ICE regimens. Although our patient population was refractory, the ORR, PFS, and OS data were found to be similar with the results of previous reports covering non-refractory cases [13, 14]. In a small study including relapsed but not refractory cases with DLBCL, ORR was reported as 57% [15]. Horn et al. reported a 55% response rate in cases similar to our population composed of 75% DLBCL [16]. The highest success rate with bendamustine
in refractory DLBCL patients has been reported in a phase II trial and the response rate was 63% [17].

Authors from Memorial Sloan Kettering Cancer Center reported an 53% ORR in cases with relapsed HL [18]. ORR with bendamustine as a single agent has been reported between 50 and 53% in cases with refractory HL [10, 11, 19]. Although the duration of response was short with a median PFS of 5 months, favorable treatment results were achieved in HL. In our study ORR was 61.1% with an estimated 1-year survival of 61.1% and 1-year estimated OS was 71.8%. AutoSCT and alloSCT were performed in 2 patients who were heavily pretreated (median 5 lines) and these 2 cases were more refractory than the previously reported cases.

Besides the efficacy of bendamustine in high grade DLBCL and refractory HL, bendamustine is a salutary treatment agent in low grade lymphomas and MCL. Earlier studies and German group trials showed favorable single agent bendamustine activity in CLL [20, 21]. Later on, Fischer reported 45% and 60% response rates in 78 cases with CLL in fludarabine refractory and naive patients, respectively [16]. The median event-free survival observed by the German group was 14.7 months. In our study group, bendamustine was used as a median fourth line agent in CLL patients, ORR was 88.2%, and estimated 1-year PFS and OS were 85.7 and 92.9%, respectively. These results show the success of bendamustine treatment in refractory CLL/SLL patients.

The efficacy of bendamustine has also been analyzed in rituximab pre-treated or refractory patients with indolent B-cell lymphomas and FL and ORR has been found between 71% and 86% [12, 14, 22–25]. In our study ORR was 72.2% in MCL, 80% in FL and 88.9% in MZL patients. A complete response was detected in 88.9% of MZL patients. At a median follow-up of 22 months, 1-year PFS was 50% in FL, 64.6% in MCL and 71.4% in MZL; and 1-year OS was 71.4% in MZL, 74.9% in MCL, and 88.9% in FL. Although our patient population is heterogeneous regarding its characteristics, the main shared feature is the refractoriness and relapse rates, which are important for determining the importance of ORR and event-free survival rates.

The major toxicities observed with bendamustine were reversible myelosuppression, infections and gastrointestinal adverse events [9, 26]. Reported infections were recurring herpes zoster infections and cytomegalovirus infections [9, 22, 25, 27]. Bendamustine was well tolerated in our patients and was not directly connected to life-threatening adverse events. Although adverse events were frequent, grade III–IV toxicity was low; namely 1% diarrhea and 14% lymphopenia. Adverse events did not cause treatment to be stopped; a one-dose delay or dose reduction was required in 25.3% and 11.1% of patients, respectively. Due to the retrospective and multicentric nature of our study, data regarding herpes zoster and CMV infections were not satisfactory. No deaths were attributed to bendamustine treatment in the median follow-up of 22 months.

In conclusion, the present study suggests that bendamustine is a promising agent in lymphoma, both in patients with low and high-grade lymphomas as well HL who have failed multiple lines of treatments. Bendamustine may represent a valuable palliative option providing high PFS rates and a reasonable option for bridging to SCT. It is important to note that OS rates were higher than PFS rates, which is also a success of bendamustine treatment since it allows further treatment beyond bendamustine, and as a bridge therapy to other treatments and SCT. However, due to its heterogeneity and retrospective nature, the power of the present study may be limited, which further clarifies the need for prospective studies.

Acknowledgments

We thank our patients and their families who participated in the research helpfully and devotedly without expecting material compensation.

Conflict of interest

The authors declare no conflict of interest.

References

1. Anderson T, Chabner BA, Young RC, et al. Malignant lymphoma. 1. The histology and staging of 473 patients at the National Cancer Institute. Cancer 1982; 50: 2699-707.
2. Pfreundschuh M, Trümper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7: 379-91.
3. Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet 2002; 359: 2065-71.
4. Tageja N. Bendamustine: safety and efficacy in the management of indolent non-Hodgkin’s lymphoma. Clin Med Insights Oncol 2011; 5: 145-56.
5. Leoni LM. Bendamustine: rescue of an effective antineoplastic agent from the mid-twentieth century. Semin Hematol 2011; 48 (Suppl 1): S4-11.
6. Knauf WU, Lissichkov T, Aldaoud A, et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009; 27: 4378-84.
7. Robinson KS, Williams ME, van der Jagt RH, et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin’s lymphoma. J Clin Oncol 2008; 26: 4473-9.
Effectiveness of bendamustine in relapsed or refractory lymphoma cases: a Turkish Oncology Group study

8. Vacirca JL, Acs PI, Tabbara IA, et al. Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma. Ann Hematol 2014; 93: 403-9.
9. Penne M, Sarraf Yazdy M, Nair KS, Cheson BD. Extended follow-up of patients treated with bendamustine for lymphoid malignancies. Clin Lymphoma Myeloma Leuk 2017; 17: 637-44.
10. Corazzelli G, Angrilli E, D’Arco A, et al. Efficacy and safety of bendamustine for the treatment of patients with recurring Hodgkin lymphoma. Br J Haematol 2013; 160: 207-15.
11. Chesquesieres H, Stamatoullas A, Casasnovas O, et al. Clinical experience of bendamustine in relapsed or refractory Hodgkin lymphoma: a retrospective analysis of the French compassionate use program in 28 patients. Leuk Lymphoma 2013; 54: 2399-404.
12. Ohmachi K, Ando K, Ogura M, et al. Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. Cancer Sci 2010; 101: 2059-64.
13. Weidmann E, Kim SZ, Rost A, et al. Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin’s lymphoma. Ann Oncol 2002; 13: 1285-9.
14. Rigacci L, Puccini B, Cortelazzo S, et al. Bendamustine with or without rituximab for the treatment of heavily pretreated non-Hodgkin’s lymphoma patients: a multicenter retrospective study on behalf of the Italian Lymphoma Foundation (ILF). Ann Hematol 2012; 91: 1013-22.
15. Walter E, Schmitt T, Dietrich S, et al. Rituximab and bendamustine in patients with CD20+ diffuse large B-cell lymphoma not eligible for cyclophosphamide, doxorubicin, vincristine and prednisone-like chemotherapy. Leuk Lymphoma 2012; 53: 2290-2.
16. Horn J, Kleber M, Hieke S, et al. Treatment option of bendamustine in combination with rituximab in elderly and frail patients with aggressive B-non-Hodgkin lymphoma: rational, efficacy, and tolerance. Ann Hematol 2012; 91: 1579-86.
17. Ohmachi K, Nihatsu N, Uchida T, et al. Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 2013; 31: 2103-9.
18. Moskowitz AJ, Hamlin PA Jr, Perales MA, et al. Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma. J Clin Oncol 2013; 31: 456-60.
19. Kharfan-Dabaja MA, Hamadani M, Sibai H, Savani BN. Managing Hodgkin lymphoma relapsing after autologous hematopoietic cell transplantation: a not-so-good cancer after all! Bone Marrow Transplant 2014; 49: 599-606.
20. Lissitchkov T, Arnauov G, Peytchev D, Merkle K. Phase-I/II study to evaluate dose limiting toxicity, maximum tolerated dose, and tolerability of bendamustine HCl in pre-treated patients with B-chronic lymphocytic leukaemia (Binet stages B and C) requiring therapy. J Cancer Res Clin Oncol 2006; 132: 99-104.
21. Bergmann MA, Goebeler ME, Herold M, et al. Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group. Haematologica 2005; 90: 1357-64.
22. Kahi BS, Bartlett NL, Leonard JP, et al. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study. Cancer 2010; 116: 106-14.